 MiMedx Group Inc NASDAQ: MDXG stock dropped after announcing top-line results from two musculoskeletal trials of micronized dehydrated Human Amnion Chorion Membrane mdHACM. Top-line results from an interim analysis of the six-month efficacy data for the Phase 2B trial for Knee Osteoarthritis KOA did not meet primary endpoints. 